GCLC and cancer: Polymorphisms of GCLM are associated with a decrease in GCLC expression in hemolytic anemia patients [80], both a decrease in GSH levels and a subsequent onset of drug resistance in cancer cell lines [81], and both reduced GCL activity and correspondingly decreased GSH levels in schizophrenia patients [82,83].